NEW YORK (GenomeWeb News) – MDxHealth and Plus Diagnostics today announced a co-promotional deal covering MDxHealth's epigenetic test for prostate cancer in the US.
Plus Diagnostics will build awareness for MDx Health's ConfirmMDx test through its national network of urologists. Financial and other terms of the deal were not disclosed.
"The national reach afforded by Plus Diagnostics provides a direct channel to the urology community and will aid in meeting the growing demand for our test," MDxHealth CEO Jan Groen said in a statement.
The epigenetic-based test for distinguishing patients with true negative biopsies from those at risk of occult cancer is performed at MDxHealth's Irvine, Calif., facility and detects an "epigenetic field effect or 'halo' associated with the cancerization process at the DNA level in cells adjacent to cancer foci," the Liege, Belgium-based company said.
Plus Diagnostics is a pathology company with locations in Union, NJ and Irvine.